These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30547005)

  • 41. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
    Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus.
    Okada K; Yagyu H; Kotani K; Miyamoto M; Osuga J; Nagasaka S; Ishibashi S
    Endocr J; 2010; 57(10):903-8. PubMed ID: 20733267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L; Parris W; Adeli K; Cheung RC
    Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method.
    Whelton SP; Meeusen JW; Donato LJ; Jaffe AS; Saenger A; Sokoll LJ; Blumenthal RS; Jones SR; Martin SS
    J Clin Lipidol; 2017; 11(4):1065-1072. PubMed ID: 28826567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.
    Ansquer JC; Corda C; Le Malicot K; Jessent V
    Curr Ther Res Clin Exp; 2009 Apr; 70(2):71-93. PubMed ID: 24683220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of apolipoprotein B, LDL-C and vascular stiffness in adolescents with type 1 diabetes.
    Bjornstad P; Nguyen N; Reinick C; Maahs DM; Bishop FK; Clements SA; Snell-Bergeon JK; Lieberman R; Pyle L; Daniels SR; Paul Wadwa R
    Acta Diabetol; 2015 Jun; 52(3):611-9. PubMed ID: 25539881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa.
    Pitso L; Mofokeng TRP; Nel R
    BMC Endocr Disord; 2021 Aug; 21(1):159. PubMed ID: 34365977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipoprotein profiles, not anthropometric measures, correlate with serum lipoprotein(a) values in children: the Taipei children heart study.
    Chu NF; Makowski L; Chang JB; Wang DJ; Liou SH; Shieh SM
    Eur J Epidemiol; 2000 Jan; 16(1):5-12. PubMed ID: 10780336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum lipid profiles and glycemic control in adolescents and young adults with type 1 diabetes mellitus.
    Kim SH; Jung IA; Jeon YJ; Cho WK; Cho KS; Park SH; Jung MH; Suh BK
    Ann Pediatr Endocrinol Metab; 2014 Dec; 19(4):191-6. PubMed ID: 25654064
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
    Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
    Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial.
    Soran H; Liu Y; Adam S; Siahmansur T; Ho JH; Schofield JD; Kwok S; Gittins M; France M; Younis N; Gibson JM; Durrington PN; Rutter MK
    J Clin Lipidol; 2018; 12(1):44-55. PubMed ID: 29246729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes.
    Sam S; Haffner S; Davidson MH; D'Agostino RB; Feinstein S; Kondos G; Perez A; Mazzone T
    Diabetes; 2008 Aug; 57(8):2022-7. PubMed ID: 18469202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents.
    Magge SN; Stettler N; Koren D; Levitt Katz LE; Gallagher PR; Mohler ER; Rader DJ
    J Clin Endocrinol Metab; 2011 May; 96(5):1549-54. PubMed ID: 21367935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.